Breaking News

You are here » Indian-Commodity  :  Corporate  :  Zydus receives USFDA's nod for Dutasteride and Tamsulosin Hydrochloride Capsules

25-May2018

Zydus receives USFDA's nod for Dutasteride and Tamsulosin Hydrochloride Capsules

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Dutasteride and Tamsulosin Hydrochloride Capsules, 0.5 mg/0.4 mg. The drug is used to treat symptoms of Benign Prostatic Hyperplasia (BPH). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies


Related News

View all news

SBI raises Rs 1,251 crore by issuing Basel III-compliant bonds

State Bank of India (SBI) has raised Rs 1,251.30 crore by issuing Basel III-compliant bonds. The Committee of Directors for Capital Raising at its meeting held on 22 March 2019 deliberated and accorded......

USFDA completes audit at Dr. Reddy's subsidiary in Hyderabad

USFDA has completed audit of R&D facility of Aurigene Discovery Technologies, a wholly owned subsidiary of Dr. Reddy's Laboratories, situated at Miyapur, Hyderabad. No FDA 483 was issued at the......

SpiceJet reports passenger load factor of 94% in February

SpiceJet has reported the Passenger Load Factor (PLF) of 94.0% during the month of February 2019. The company had reported PLF of 90.9% during the month of January 2019.The PLF is a key indicator of the......

Top News

View all news

Infosys to enter into agreement with The House Fund II

Infosys is going to enter into an agreement with The House Fund II, L.P., an AI-focused fund targeting startups from the University of California - Berkeley, committing to invest $10.0 million.......

EID Parry receives approval for investment Rs 70 crore in PSRIPL

EID Parry (INDIA) has received approval for investment upto Rs 70 crore in the equity share capital of Parry Sugars Refinery India (PSRIPL), a wholly owned subsidiary of the Company. The Board of directors......

SBI raises Rs 1,251 crore by issuing Basel III-compliant bonds

State Bank of India (SBI) has raised Rs 1,251.30 crore by issuing Basel III-compliant bonds. The Committee of Directors for Capital Raising at its meeting held on 22 March 2019 deliberated and accorded......